<DOC>
	<DOC>NCT01642667</DOC>
	<brief_summary>The aim of this study is to elucidate the efficacy and safety of pharmacoinvasive therapy by using prourokinase (prouk), a unique fibrin-specific agent, in patients with ST-segment elevation myocardial infarction (STEMI)</brief_summary>
	<brief_title>Pharmacoinvasive Therapy With Prourokinase</brief_title>
	<detailed_description />
	<mesh_term>Infarction</mesh_term>
	<mesh_term>Myocardial Infarction</mesh_term>
	<mesh_term>Saruplase</mesh_term>
	<criteria>age 75 years or younger, symptom onset 6 h or less before randomization, intention to undertake primary PCI, STsegment elevation of 2 mm or more in two anterior leads or of 1 mm or more in two inferior leads if they had STsegment elevation, or new left bundlebranch block. expected arrival at the catheterization laboratory less than 1 h or more than 3 h after randomization, anticipated problems with vascular access, previous enrollment to other studies, and the usual contraindications to thrombolytic therapy.</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>July 2012</verification_date>
</DOC>